

Gilead Announces Senior Management Promotion

February 2, 2009 2:02 PM ET

FOSTER CITY, Calif., Feb 02, 2009 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of Andrew Cheng, MD, PhD to the newly created role of Senior Vice President, Development Operations. In this role, Dr. Cheng will be responsible for Gilead's biometrics, clinical operations, drug safety and public health, project and portfolio management, and regulatory affairs activities, reporting to Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer. With his promotion, Dr. Cheng will join Gilead's Executive Committee.

Dr. Cheng joined Gilead in 1999 and most recently served as Vice President, Clinical Research, overseeing clinical development activities for the company's development-stage programs in HIV/AIDS. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. He received his medical degree and PhD in Cellular and Molecular Biology from Columbia University and undergraduate degree from the Johns Hopkins University.

"Over the past decade, Andrew has played a key leadership role overseeing multiple clinical programs, including pivotal studies supporting the approval of our HIV medications and clinical program design for our investigational HIV candidate, elvitegravir, and our novel pharmacoenhancer, GS 9350," commented Dr. Bischofberger. "With a growing number of programs currently in our research and development pipeline and the increasing complexity of our business, Andrew's new role will help us maintain an efficient and cost-effective approach to development, enhancing collaboration across our four therapeutic areas and ensuring we can advance promising candidates as quickly as possible."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.

SOURCE: Gilead Sciences, Inc.

Gilead Sciences, Inc.

Patrick O'Brien, Investors, 650-522-1936

Amy Flood, Media, 650-522-5643